m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05647
 [1]
m6A modification PVT1 PVT1 YTHDC1 : m6A sites Direct Enhancement Non-coding RNA PVT1 IL33  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator YTH domain-containing protein 1 (YTHDC1) READER
 Regulator Info 
m6A Target Pvt1 oncogene (PVT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Pvt1 oncogene (PVT1) LncRNA View Details
Regulated Target Interleukin-33 (IL33) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Pvt1 oncogene (PVT1) positively regulated Interleukin-33 (IL33) expression by recruiting YTHDC1 to mediate m6A modification of IL-33. In conclusion, silencing PVT1 demonstrated beneficial effects in alleviating BPD by facilitating YTHDC1-mediated m6A modification of IL-33.
Responsed Disease Chronic respiratory disease originating in the perinatal period ICD-11: KB29.0
 Disease Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell apoptosis
In-vitro Model
MLE-12
 N.A. Mus musculus CVCL_3751
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
In-vivo Model Before hyperoxia treatment, mice in the BPD/PVT1 KO group were intratracheally instilled with 5 μL adenovirus vector expressing sh-PVT1 at a titer of 1 × 109 pfu/100 μL. Mice in the BPD/PVT1 KO + IL-33 group were intratracheally instilled with 5 μL adenovirus vector expressing sh-PVT1 and 5 μL adenovirus vector expressing IL-33.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Interleukin-33 (IL33) 6 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Tozorakimab Phase 3 [2]
MOA Inhibitor
External Link
TTD: D0YFN1
 Compound Name SAR440340 Phase 3 [3]
Synonyms
Itepekimab
    Click to Show/Hide
External Link
TTD: D8U1EX
 Compound Name MEDI3506 Phase 3 [4]
Synonyms
Tozorakimab
    Click to Show/Hide
External Link
TTD: DOTF14
 Compound Name Itepekimab Phase 3 [3]
External Link
TTD: DPT90B
 Compound Name AMG 282 Phase 1 [5]
External Link
TTD: D07GDR
 Compound Name PF-07264660 Phase 1 [6]
External Link
TTD: D1LP4B
References
Ref 1 Recruitment of PVT1 Enhances YTHDC1-Mediated m6A Modification of IL-33 in Hyperoxia-Induced Lung Injury During Bronchopulmonary Dysplasia. Inflammation. 2024 Apr;47(2):469-482. doi: 10.1007/s10753-023-01923-1. Epub 2023 Nov 2.
Ref 2 ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.
Ref 3 Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668.
Ref 4 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
Ref 5 Clinical pipeline report, company report or official report of Amgen.
Ref 6 Clinical pipeline report, company report or official report of Pfizer